A phase II trial of nivolumab and denosumab association as second-line treatment for stage IV non-small-cell lung cancer (NSCLC) with bone metastases: DENIVOS study (GFPC 06-2017) - UFR SVE Sciences de la vie et de l'environnement Accéder directement au contenu
Article Dans Une Revue Annals of Oncology Année : 2022

A phase II trial of nivolumab and denosumab association as second-line treatment for stage IV non-small-cell lung cancer (NSCLC) with bone metastases: DENIVOS study (GFPC 06-2017)

Domaines

Cancer

Dates et versions

hal-03924732 , version 1 (05-01-2023)

Identifiants

Citer

C Decroisette, I. Monnet, C Ricordel, A. Demaegdt, L Falchero, et al.. A phase II trial of nivolumab and denosumab association as second-line treatment for stage IV non-small-cell lung cancer (NSCLC) with bone metastases: DENIVOS study (GFPC 06-2017). Annals of Oncology, 2022, 33 (7), pp.S1028-S1029. ⟨10.1016/j.annonc.2022.07.1161⟩. ⟨hal-03924732⟩
19 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More